偏头痛相关污名及其与失能、发作间期负担和生活质量的关系:OVERCOME(美国)研究结果
OVERCOME(美国)是一项基于网络的观察性研究,每年招募具有人口学代表性的美国样本,使用经验证的偏头痛诊断问卷识别活动性偏头痛患者,并采用新型12条目偏头痛相关污名问卷(MiRS)评估污名频率。在59,001例活动性偏头痛患者中,31.7%经常或非常频繁地经历偏头痛相关污名,且该比例随每月头痛天数增加而升高;偏头痛相关污名与更严重的失能、更大的发作间期负担和更差的生活质量相关。
要点
- 31.7%的活动性偏头痛患者经常或非常频繁地经历偏头痛相关污名。
- 偏头痛相关污名经常或非常频繁的比例从每月头痛天数<4天的25.5%升至≥15天的47.5%。
- 与MiRS-Never组相比,MiRS-Both组失能风险比率为2.68(95%CI 2.56-2.80)。
核心结论
- OVERCOME(美国)研究发现,31.7%的偏头痛患者经常或非常频繁地经历偏头痛相关污名,且偏头痛相关污名与更严重的失能、更大的发作间期负担和更差的生活质量相关。
研究设计与样本
- OVERCOME(美国)是一项基于网络的观察性研究,每年招募具有人口学代表性的美国样本,并使用经验证的偏头痛诊断问卷识别活动性偏头痛患者。
- 使用新型12条目偏头痛相关污名问卷(MiRS)评估偏头痛相关污名,该问卷包含2个因子:认为他人视偏头痛为获取继发性获益(8条目,α=0.92)和认为他人在最小化疾病负担(4条目,α=0.86)。
- 定义5组:MiRS-Both(继发性获益和最小化负担均经常/非常频繁)、MiRS-SG(继发性获益经常/非常频繁)、MiRS-MB(最小化负担经常/非常频繁)、MiRS-Rarely/Sometimes、MiRS-Never。
- 以MiRS组为自变量,在控制社会人口学特征、临床特征和每月头痛天数分类后,横断面建模其与失能(偏头痛失能评估量表,MIDAS)、发作间期负担(偏头痛发作间期负担量表-4)和偏头痛特异性生活质量(偏头痛特异性生活质量量表v2.1角色功能-限制性)的关系。
主要发现
- 在活动性偏头痛的基于人群样本(n=59,001)中,平均年龄41.3岁,受访者以女性(74.9%)和白人(70.1%)为主。
- 41.1%的受访者平均每月头痛天数≥4天,31.7%的受访者经常或非常频繁地经历偏头痛相关污名。
- 经常或非常频繁经历偏头痛相关污名的比例从每月头痛天数<4天者的25.5%增加至每月头痛天数≥15天者的47.5%。
- 与MiRS-Never组相比,每个MiRS组失能(MIDAS评分)增加的风险均显著;MiRS-Both组风险增加超过两倍(率比2.68,95%CI 2.56-2.80)。
- 对于失能、发作间期负担和偏头痛特异性生活质量,偏头痛相关污名增加与所有每月头痛天数分类下的疾病负担增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: This population-based analysis characterizes the relative frequency of migraine-related stigma and its cross-sectional relationship to migraine outcomes. We hypothesized that migraine-related stigma would be inversely associated with favorable migraine outcomes across headache day categories. METHODS: OVERCOME (US) is a web-based observational study that annually recruited a demographically representative US sample and then identified people with active migraine using a validated migraine diagnostic questionnaire. It also assessed how frequently respondents experienced migraine-related stigma using a novel 12-item questionnaire (Migraine-Related Stigma, MiRS) that contained 2 factors; feeling that others viewed migraine as being used for Secondary Gain (8 items, α = 0.92) and feeling that others were Minimizing disease Burden (4 items, α = 0.86). We defined 5 groups: (1) MiRS-Both (Secondary Gain and Minimizing Burden often/very often; (2) MiRS-SG (Secondary Gain often/very often); (3) MiRS-MB (Minimizing Burden often/very often); (4) MiRS-Rarely/Sometimes; (5) MiRS-Never. Using MiRS group as the independent variable, we modeled its cross-sectional relationship to disability (Migraine Disability Assessment, MIDAS), interictal burden (Migraine Interictal Burden Scale-4), and migraine-specific quality of life (Migraine Specific Quality of Life v2.1 Role Function-Restrictive) while controlling for sociodemographics, clinical features, and monthly headache day categories. RESULTS: Among this population-based sample with active migraine (n = 59,001), mean age was 41.3 years and respondents predominantly identified as female (74.9%) and as White (70.1%). Among respondents, 41.1% reported experiencing, on average, ≥4 monthly headache days and 31.7% experienced migraine-related stigma often/very often; the proportion experiencing migraine-related stigma often/very often increased from 25.5% among those with <4 monthly headache days to 47.5% among those with ≥15 monthly headache days. The risk for increased disability (MIDAS score) was significant for each MiRS group compared with the MiRS-Never group; the risk more than doubled for the MiRS-Both group (rate ratio 2.68, 95% CI 2.56-2.80). For disability, interictal burden, and migraine-specific quality of life, increased migraine-related stigma was associated with increased disease burden across all monthly headache day categories. DISCUSSION: OVERCOME (US) found that 31.7% of people with migraine experienced migraine-related stigma often/very often and was associated with more disability, greater interictal burden, and reduced quality of life.
引用
- Shapiro RE, Nicholson RA, Seng EK, et al. Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life: Results of the OVERCOME (US) Study. Neurology. 2024. PMID: 38232340. doi:10.1212/WNL.0000000000208074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。